

Victor H Engelhard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3229106/publications.pdf>

Version: 2024-02-01

128
papers

10,321
citations

28274

55
h-index

34986

98
g-index

139
all docs

139
docs citations

139
times ranked

9149
citing authors

#	ARTICLE	IF	CITATIONS
1	An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. <i>Cancer Cell</i> , 2022, 40, 524-544.e5.	16.8	23
2	Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. <i>Cancer Immunology Research</i> , 2021, 9, 583-597.	3.4	9
3	Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. , 2021, 9, e002273.		39
4	Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. <i>Cell Reports</i> , 2021, 36, 109422.	6.4	89
5	Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates. <i>Journal of Translational Medicine</i> , 2021, 19, 371.	4.4	9
6	Phospho- β -catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2. <i>Pathology Research and Practice</i> , 2021, 224, 153527.	2.3	2
7	Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients. <i>Cancer Immunology Research</i> , 2021, 9, 1327-1341.	3.4	4
8	Antibiotics Drive Microbial Imbalance and Vitiligo Development in Mice. <i>Journal of Investigative Dermatology</i> , 2020, 140, 676-687.e6.	0.7	38
9	Immunomodulation of intracranial melanoma in response to blood-tumor barrier opening with focused ultrasound. <i>Theranostics</i> , 2020, 10, 8821-8833.	10.0	25
10	Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, 1338-1345.	3.4	44
11	MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. , 2020, 8, e000262.		44
12	Abstract B68: Pre-existing immune memory to cancer-associated phosphopeptides in healthy donors. , 2020, , .		0
13	Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1121-1132.	4.2	13
14	The Antigen Processing and Presentation Machinery in Lymphatic Endothelial Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1033.	4.8	70
15	Comparative Transcriptomic Analysis Identifies a Range of Immunologically Related Functional Elaborations of Lymph Node Associated Lymphatic and Blood Endothelial Cells. <i>Frontiers in Immunology</i> , 2019, 10, 816.	4.8	35
16	The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis. <i>Annals of Surgery</i> , 2019, 270, 712-722.	4.2	14
17	Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. <i>Journal of Immunology</i> , 2018, 200, 432-442.	0.8	153
18	Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. <i>Oncolimmunology</i> , 2018, 7, e1490855.	4.6	10

#	ARTICLE	IF	CITATIONS
19	Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. <i>Methods in Molecular Biology</i> , 2018, 1845, 241-257.	0.9	18
20	Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1338-1354.	8.2	64
21	Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry. <i>Cancer Immunology Research</i> , 2017, 5, 1062-1073.	3.4	29
22	Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma. <i>Journal of Proteome Research</i> , 2017, 16, 228-237.	3.7	34
23	The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status. <i>Oncotarget</i> , 2017, 8, 54160-54172.	1.8	42
24	Abstract 4609: Agenus™ next generation cancer vaccine platforms. , 2017, , .		0
25	Effect of cancer vaccine formulation on synergy with anti-CTLA-4 and anti-PD-L1 checkpoint blockade therapy of cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3094-3094.	1.6	0
26	Abstract A031: Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. , 2016, , .		0
27	Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. <i>Advances in Cancer Research</i> , 2015, 128, 263-307.	5.0	123
28	Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. <i>Nature Communications</i> , 2015, 6, 7114.	12.8	139
29	Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction. <i>Nature Communications</i> , 2015, 6, 6771.	12.8	138
30	Abstract IA23: T cell trafficking in lymphoid and non-lymphoid tissues. , 2015, , .		0
31	Regulation of T-cell Tolerance by Lymphatic Endothelial Cells. <i>Journal of Clinical & Cellular Immunology</i> , 2014, 05, .	1.5	40
32	Immune responses in a mouse model of vitiligo with spontaneous epidermal deãand repigmentation. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1075-1085.	3.3	27
33	MHC-Restricted Phosphopeptides from Insulin Receptor Substrate-2 and CDC25b Offer Broad-Based Immunotherapeutic Agents for Cancer. <i>Cancer Research</i> , 2014, 74, 6784-6795.	0.9	28
34	Tolerogenic Properties of Lymphatic Endothelial Cells Are Controlled by the Lymph Node Microenvironment. <i>PLoS ONE</i> , 2014, 9, e87740.	2.5	95
35	MHC Class IãAssociated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia. <i>Science Translational Medicine</i> , 2013, 5, 203ra125.	12.4	186
36	Peripheral Tissue Homing Receptors Enable T Cell Entry into Lymph Nodes and Affect the Anatomical Distribution of Memory Cells. <i>Journal of Immunology</i> , 2013, 191, 2412-2425.	0.8	25

#	ARTICLE	IF	CITATIONS
37	Regulatory T cells and vasectomy. <i>Journal of Reproductive Immunology</i> , 2013, 100, 66-75.	1.9	28
38	Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity. <i>Cancer Cell</i> , 2013, 23, 516-526.	16.8	131
39	Peripheral Tissue Homing Receptor Control of Naïve, Effector, and Memory CD8 T Cell Localization in Lymphoid and Non-Lymphoid Tissues. <i>Frontiers in Immunology</i> , 2013, 4, 241.	4.8	42
40	Lymphatic endothelial cells - key players in regulation of tolerance and immunity. <i>Frontiers in Immunology</i> , 2012, 3, 305.	4.8	66
41	Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. <i>Blood</i> , 2012, 120, 4772-4782.	1.4	256
42	Abstract 512: Leukemia-specific immunity in healthy individuals and patients post-transplant targets phosphorylated tumor antigens. , 2012, , .		0
43	Abstract 1584: MHC-restricted phosphopeptides as broad-based immunotherapeutic targets for cancer. , 2012, , .		0
44	Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. <i>Journal of Experimental Medicine</i> , 2010, 207, 1791-1804.	8.5	211
45	CD8 T Cells Activated in Distinct Lymphoid Organs Differentially Express Adhesion Proteins and Coexpress Multiple Chemokine Receptors. <i>Journal of Immunology</i> , 2010, 184, 4079-4086.	0.8	55
46	Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. <i>Journal of Experimental Medicine</i> , 2010, 207, 681-688.	8.5	321
47	Mechanisms of Spatial and Temporal Development of Autoimmune Vitiligo in Tyrosinase-Specific TCR Transgenic Mice. <i>Journal of Immunology</i> , 2010, 184, 1909-1917.	0.8	100
48	Targeting allergen to FcÎ³RI reveals a novel TH2 regulatory pathway linked to thymic stromal lymphopoietin receptor. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 247-256.e8.	2.9	36
49	Structural Basis for the Presentation of Tumor-Associated MHC Class II-Restricted Phosphopeptides to CD4+ T Cells. <i>Journal of Molecular Biology</i> , 2010, 399, 596-603.	4.2	37
50	Abstract B14: A phosphorylated Î²-catenin peptide that is presented by HLA-A2 MHC molecules generates strong phosphospecific T cell responses against melanoma. , 2010, , .		0
51	Immunologically Targeting the Leukaemia Phosphoproteome. <i>Blood</i> , 2010, 116, 1016-1016.	1.4	0
52	Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12073-12078.	7.1	98
53	N-Glycosylation Enhances Presentation of a MHC Class I-Restricted Epitope from Tyrosinase. <i>Journal of Immunology</i> , 2009, 182, 4830-4835.	0.8	28
54	Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3889-3894.	7.1	36

#	ARTICLE	IF	CITATIONS
55	Strategies and challenges in eliciting immunity to melanoma. <i>Immunological Reviews</i> , 2008, 222, 28-42.	6.0	19
56	Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. <i>Nature Immunology</i> , 2008, 9, 1236-1243.	14.5	130
57	Targeting Fc ϵ 1 to Fc γ RI induces a novel variation of the TH2 response in subjects with cat allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 756-762.e4.	2.9	25
58	Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases. <i>Journal of Immunology</i> , 2008, 180, 130-137.	0.8	55
59	Activated CD8 T Cells Redistribute to Antigen-Free Lymph Nodes and Exhibit Effector and Memory Characteristics. <i>Journal of Immunology</i> , 2008, 181, 1814-1824.	0.8	17
60	MHC Class II Presentation of gp100 Epitopes in Melanoma Cells Requires the Function of Conventional Endosomes and Is Influenced by Melanosomes. <i>Journal of Immunology</i> , 2008, 181, 7843-7852.	0.8	39
61	Tumor-associated MHC II-restricted phosphopeptides: New targets for immune recognition. <i>FASEB Journal</i> , 2008, 22, 1079.1.	0.5	1
62	NKT Cell Activation Mediates Neutrophil IFN- γ Production and Renal Ischemia-Reperfusion Injury. <i>Journal of Immunology</i> , 2007, 178, 5899-5911.	0.8	307
63	Dendritic Cell Immunization Route Determines Integrin Expression and Lymphoid and Nonlymphoid Tissue Distribution of CD8 T Cells. <i>Journal of Immunology</i> , 2007, 178, 1512-1522.	0.8	30
64	Deletional Self-Tolerance to a Melanocyte/Melanoma Antigen Derived from Tyrosinase Is Mediated by a Radio-Resistant Cell in Peripheral and Mesenteric Lymph Nodes. <i>Journal of Immunology</i> , 2007, 179, 993-1003.	0.8	132
65	The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes. <i>International Journal of Mass Spectrometry</i> , 2007, 259, 32-39.	1.5	20
66	Immune Targeting of the Phosphoproteome in Lymphoma and Leukemia.. <i>Blood</i> , 2007, 110, 285-285.	1.4	1
67	Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. <i>Journal of Experimental Medicine</i> , 2006, 203, 2639-2648.	8.5	271
68	The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. <i>Blood</i> , 2006, 107, 3779-3786.	1.4	99
69	Post-translational modifications of naturally processed MHC-binding epitopes. <i>Current Opinion in Immunology</i> , 2006, 18, 92-97.	5.5	109
70	Immunity to Melanoma Antigens: From Self-Tolerance to Immunotherapy. <i>Advances in Immunology</i> , 2006, 90, 243-295.	2.2	55
71	Peptide and Dendritic Cell Vaccines. <i>Clinical Cancer Research</i> , 2006, 12, 2342s-2345s.	7.0	30
72	Limited Infiltration of Exogenous Dendritic Cells and Naive T Cells Restricts Immune Responses in Peripheral Lymph Nodes. <i>Journal of Immunology</i> , 2006, 176, 4535-4542.	0.8	19

#	ARTICLE	IF	CITATIONS
73	Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14889-14894.	7.1	168
74	Processing of a Class I-Restricted Epitope from Tyrosinase Requires Peptide N-Glycanase and the Cooperative Action of Endoplasmic Reticulum Aminopeptidase 1 and Cytosolic Proteases. Journal of Immunology, 2006, 177, 5440-5450.	0.8	40
75	Incomplete Differentiation of Antigen-Specific CD8 T Cells in Tumor-Draining Lymph Nodes. Journal of Immunology, 2006, 177, 6081-6090.	0.8	55
76	Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. Journal of Cell Biology, 2006, 175, i9-i9.	5.2	1
77	Sphingosine Kinase 2 Is Required for Modulation of Lymphocyte Traffic by FTY720. Journal of Biological Chemistry, 2005, 280, 36865-36872.	3.4	198
78	Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma. Journal of Immunology, 2005, 174, 6863-6871.	0.8	91
79	Regulated Folding of Tyrosinase in the Endoplasmic Reticulum Demonstrates That Misfolded Full-Length Proteins Are Efficient Substrates for Class I Processing and Presentation. Journal of Immunology, 2005, 174, 2544-2551.	0.8	39
80	Identification of Novel and Widely Expressed Cancer/Testis Gene Isoforms That Elicit Spontaneous Cytotoxic T-Lymphocyte Reactivity to Melanoma. Cancer Research, 2004, 64, 1157-1163.	0.9	21
81	Creating new peptide antigens by slicing and splicing proteins. Nature Immunology, 2004, 5, 128-129.	14.5	6
82	Preventing the Spontaneous Modification of an HLA-A2-Restricted Peptide at an N-Terminal Glutamine or an Internal Cysteine Residue Enhances Peptide Antigenicity. Journal of Immunotherapy, 2004, 27, 177-183.	2.4	9
83	Competition Among Peptides in Melanoma Vaccines for Binding to MHC Molecules. Journal of Immunotherapy, 2004, 27, 425-431.	2.4	14
84	Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes. Immunology Letters, 2003, 90, 131-135.	2.5	11
85	Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. British Journal of Haematology, 2003, 123, 671-675.	2.5	49
86	Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells. Journal of Clinical Oncology, 2003, 21, 4016-4026.	1.6	303
87	Tapasin Is a Facilitator, Not an Editor, of Class I MHC Peptide Binding. Journal of Immunology, 2003, 171, 5287-5295.	0.8	103
88	Antigen Density Presented By Dendritic Cells In Vivo Differentially Affects the Number and Avidity of Primary, Memory, and Recall CD8+ T Cells. Journal of Immunology, 2003, 170, 1822-1829.	0.8	116
89	Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control. Journal of Experimental Medicine, 2003, 198, 1023-1034.	8.5	196
90	The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood, 2003, 102, 621-629.	1.4	118

#	ARTICLE	IF	CITATIONS
91	Analysis of MHC Class II Antigen Processing by Quantitation of Peptides that Constitute Nested Sets. <i>Journal of Immunology</i> , 2002, 169, 5089-5097.	0.8	88
92	Identification by Mass Spectrometry of CD8+-T-Cell Mycobacterium tuberculosis Epitopes within the Rv0341 Gene Product. <i>Infection and Immunity</i> , 2002, 70, 2926-2932.	2.2	43
93	Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. <i>Molecular Immunology</i> , 2002, 39, 127-137.	2.2	61
94	Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinical study. <i>International Journal of Cancer</i> , 2002, 98, 221-227.	5.1	28
95	Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. <i>Immunological Reviews</i> , 2002, 188, 136-146.	6.0	117
96	Tyrosinase Degradation via Two Pathways during Reverse Translocation to the Cytosol. <i>Biochemical and Biophysical Research Communications</i> , 2001, 285, 313-319.	2.1	20
97	Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. <i>International Journal of Cancer</i> , 2001, 92, 703-711.	5.1	114
98	Determination of Intronic Sequences Adjacent to an Exon Using Polymerase Chain Reaction and Genomic DNA Library Constructed by TA Cloning. <i>Analytical Biochemistry</i> , 2001, 289, 289-292.	2.4	1
99	The Immunogenicity of a New Human Minor Histocompatibility Antigen Results from Differential Antigen Processing. <i>Journal of Experimental Medicine</i> , 2001, 193, 195-206.	8.5	191
100	The HA-2 Minor Histocompatibility Antigen Is Derived from a Diallelic Gene Encoding a Novel Human Class I Myosin Protein. <i>Journal of Immunology</i> , 2001, 167, 3223-3230.	0.8	125
101	Manipulation of Avidity to Improve Effectiveness of Adoptively Transferred CD8+ T Cells for Melanoma Immunotherapy in Human MHC Class I-Transgenic Mice. <i>Journal of Immunology</i> , 2001, 167, 5824-5831.	0.8	79
102	Differences in the Expression of Human Class I MHC Alleles and Their Associated Peptides in the Presence of Proteasome Inhibitors. <i>Journal of Immunology</i> , 2001, 167, 1212-1221.	0.8	77
103	Immune Responses to the HLA-A*0201-Restricted Epitopes of Tyrosinase and Glycoprotein 100 Enable Control of Melanoma Outgrowth in HLA-A*0201-Transgenic Mice. <i>Journal of Immunology</i> , 2001, 167, 4853-4860.	0.8	48
104	Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. , 2001, 92, 703.		1
105	Pseudomonas Exotoxin-Mediated Delivery of Exogenous Antigens to MHC Class I and Class II Processing Pathways. <i>Cellular Immunology</i> , 2000, 203, 75-83.	3.0	18
106	Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. <i>Cancer Immunology, Immunotherapy</i> , 2000, 48, 661-672.	4.2	89
107	Immunodominance Among EBV-Derived Epitopes Restricted by HLA-B27 Does Not Correlate with Epitope Abundance in EBV-Transformed B-Lymphoblastoid Cell Lines. <i>Journal of Immunology</i> , 2000, 164, 6120-6129.	0.8	73
108	The Density of Peptides Displayed by Dendritic Cells Affects Immune Responses to Human Tyrosinase and gp100 in HLA-A2 Transgenic Mice. <i>Journal of Immunology</i> , 2000, 164, 2354-2361.	0.8	92

#	ARTICLE	IF	CITATIONS
109	Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen. <i>Journal of Experimental Medicine</i> , 2000, 191, 1221-1232.	8.5	154
110	Phosphorylated Peptides Are Naturally Processed and Presented by Major Histocompatibility Complex Class I Molecules in Vivo. <i>Journal of Experimental Medicine</i> , 2000, 192, 1755-1762.	8.5	192
111	Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. , 1999, 82, 669-677.		77
112	Terminal modifications inhibit proteolytic degradation of an immunogenic mart-127-35 peptide: Implications for peptide vaccines. <i>International Journal of Cancer</i> , 1999, 83, 326-334.	5.1	152
113	The Minor Histocompatibility Antigen HA-1: A Diallelic Gene with a Single Amino Acid Polymorphism. <i>Science</i> , 1998, 279, 1054-1057.	12.6	399
114	The Class I Antigen-processing Pathway for the Membrane Protein Tyrosinase Involves Translation in the Endoplasmic Reticulum and Processing in the Cytosol. <i>Journal of Experimental Medicine</i> , 1998, 187, 37-48.	8.5	109
115	The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68. <i>Journal of Experimental Medicine</i> , 1997, 185, 695-706.	8.5	125
116	The HLA-A*0201-Restricted H-Y Antigen Contains a Posttranslationally Modified Cysteine That Significantly Affects T Cell Recognition. <i>Immunity</i> , 1997, 6, 273-281.	14.3	275
117	A <i>Listeria monocytogenes</i> Pentapeptide Is Presented to Cytolytic T Lymphocytes by the H2-M3 MHC Class Ib Molecule. <i>Immunity</i> , 1996, 5, 73-79.	14.3	109
118	Conservation of minor histocompatibility antigens between human and non-human primates. <i>European Journal of Immunology</i> , 1996, 26, 2680-2685.	2.9	16
119	Direct identification of tumor-associated peptide antigens. <i>Seminars in Immunopathology</i> , 1996, 18, 171-183.	4.0	8
120	Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. <i>International Immunology</i> , 1995, 7, 597-605.	4.0	77
121	Human H-Y: a Male-Specific Histocompatibility Antigen Derived from the SMCY Protein. <i>Science</i> , 1995, 269, 1588-1590.	12.6	345
122	Structure of peptides associated with MHC class I molecules. <i>Current Opinion in Immunology</i> , 1994, 6, 13-23.	5.5	196
123	Direct analysis of tumor-associated peptide antigens. <i>Current Opinion in Immunology</i> , 1994, 6, 733-740.	5.5	58
124	Structure of Peptides Associated with Class I and Class II MHC Molecules. <i>Annual Review of Immunology</i> , 1994, 12, 181-207.	21.8	365
125	Mass Spectrometric Analysis of Peptides Associated with the Human Class I MHC Molecules HLA-A2.1 and HLA-B7 and Identification of Structural Features that Determine Binding. <i>Chemical Immunology and Allergy</i> , 1993, 57, 39-62.	1.7	17
126	Mass Spectrometric Analysis of Peptides Associated with the Human Class I MHC Molecules HLA-A2.1 and HLA-B7 and Identification of Structural Features that Determine Binding. <i>Chemical Immunology and Allergy</i> , 1993, 57, 39-62.	1.7	19

#	ARTICLE	IF	CITATIONS
127	Cell-cell adhesion mediated by CD8 and MHC class I molecules. <i>Nature</i> , 1988, 336, 79-81.	27.8	408
128	Immune Mechanisms Orchestrate Tertiary Lymphoid Structures in Tumors Via Cancer-Associated Fibroblasts. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4